Rubitecan
鲁比特康
Report date: 2023/04/25 13:50:53
NME
Base Information
Drug NameRubitecan
Drug Alias Name +[11]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[17]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesZhejiang Hisun Pharmaceutical Co LtdQilu Pharmaceutical Co LtdChengdu Naiqieer Biotechnology Co Ltd +[5]
China Registration ClassClass 1 Chemical Drug in China
Develop Information
Active CompaniesN/A
Inactive CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[6]
Active IndicationsN/A
Inactive Indications +[17]